JP2018508523A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018508523A5 JP2018508523A5 JP2017546149A JP2017546149A JP2018508523A5 JP 2018508523 A5 JP2018508523 A5 JP 2018508523A5 JP 2017546149 A JP2017546149 A JP 2017546149A JP 2017546149 A JP2017546149 A JP 2017546149A JP 2018508523 A5 JP2018508523 A5 JP 2018508523A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- cochleates
- cocreatate
- tissue
- active substance
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 22
- 239000013543 active substance Substances 0.000 claims 12
- 210000001519 tissue Anatomy 0.000 claims 11
- 229940079593 drug Drugs 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 8
- 239000002245 particle Substances 0.000 claims 5
- 150000001768 cations Chemical class 0.000 claims 4
- 150000002632 lipids Chemical class 0.000 claims 3
- 150000003904 phospholipids Chemical class 0.000 claims 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 2
- 229910052791 calcium Inorganic materials 0.000 claims 2
- 239000011575 calcium Substances 0.000 claims 2
- 229910052751 metal Inorganic materials 0.000 claims 2
- 239000002184 metal Substances 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 206010036790 Productive cough Diseases 0.000 claims 1
- 101000924393 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Vacuolar aminopeptidase 1 Proteins 0.000 claims 1
- 108020004459 Small interfering RNA Proteins 0.000 claims 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims 1
- 210000000577 adipose tissue Anatomy 0.000 claims 1
- 210000004100 adrenal gland Anatomy 0.000 claims 1
- 230000000507 anthelmentic effect Effects 0.000 claims 1
- 230000000843 anti-fungal effect Effects 0.000 claims 1
- 229940124599 anti-inflammatory drug Drugs 0.000 claims 1
- 230000000842 anti-protozoal effect Effects 0.000 claims 1
- 230000000692 anti-sense effect Effects 0.000 claims 1
- 229940124350 antibacterial drug Drugs 0.000 claims 1
- 229940121375 antifungal agent Drugs 0.000 claims 1
- 239000003524 antilipemic agent Substances 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 229940041181 antineoplastic drug Drugs 0.000 claims 1
- 239000003904 antiprotozoal agent Substances 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 229910052788 barium Inorganic materials 0.000 claims 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 claims 1
- 239000003781 beta lactamase inhibitor Substances 0.000 claims 1
- 229940126813 beta-lactamase inhibitor Drugs 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 210000000845 cartilage Anatomy 0.000 claims 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 235000015872 dietary supplement Nutrition 0.000 claims 1
- 210000000232 gallbladder Anatomy 0.000 claims 1
- 238000001415 gene therapy Methods 0.000 claims 1
- 210000002216 heart Anatomy 0.000 claims 1
- 210000003016 hypothalamus Anatomy 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 210000000936 intestine Anatomy 0.000 claims 1
- 210000005067 joint tissue Anatomy 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 210000000265 leukocyte Anatomy 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 210000001165 lymph node Anatomy 0.000 claims 1
- 229910052749 magnesium Inorganic materials 0.000 claims 1
- 239000011777 magnesium Substances 0.000 claims 1
- -1 magnesium or barium Chemical class 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 239000002664 nootropic agent Substances 0.000 claims 1
- 230000001777 nootropic effect Effects 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 230000001817 pituitary effect Effects 0.000 claims 1
- 230000036470 plasma concentration Effects 0.000 claims 1
- 239000000047 product Substances 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 210000000952 spleen Anatomy 0.000 claims 1
- 210000003802 sputum Anatomy 0.000 claims 1
- 208000024794 sputum Diseases 0.000 claims 1
- 210000001179 synovial fluid Anatomy 0.000 claims 1
- 210000001550 testis Anatomy 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 210000001541 thymus gland Anatomy 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 210000003932 urinary bladder Anatomy 0.000 claims 1
- 210000004291 uterus Anatomy 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
- 239000011782 vitamin Substances 0.000 claims 1
- 229940088594 vitamin Drugs 0.000 claims 1
- 229930003231 vitamin Natural products 0.000 claims 1
- 235000013343 vitamin Nutrition 0.000 claims 1
- 229910052725 zinc Inorganic materials 0.000 claims 1
- 239000011701 zinc Substances 0.000 claims 1
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562127799P | 2015-03-03 | 2015-03-03 | |
| US62/127,799 | 2015-03-03 | ||
| US201562162425P | 2015-05-15 | 2015-05-15 | |
| US62/162,425 | 2015-05-15 | ||
| US201562163212P | 2015-05-18 | 2015-05-18 | |
| US62/163,212 | 2015-05-18 | ||
| US201562239675P | 2015-10-09 | 2015-10-09 | |
| US62/239,675 | 2015-10-09 | ||
| US201562247641P | 2015-10-28 | 2015-10-28 | |
| US62/247,641 | 2015-10-28 | ||
| US201562264164P | 2015-12-07 | 2015-12-07 | |
| US62/264,164 | 2015-12-07 | ||
| PCT/US2016/020722 WO2016141203A1 (en) | 2015-03-03 | 2016-03-03 | Cochleates and methods of using the same to enhance tissue penetration of pharmacologically active agent |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018508523A JP2018508523A (ja) | 2018-03-29 |
| JP2018508523A5 true JP2018508523A5 (cg-RX-API-DMAC7.html) | 2019-03-28 |
| JP6770524B2 JP6770524B2 (ja) | 2020-10-14 |
Family
ID=56848705
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017546149A Active JP6770524B2 (ja) | 2015-03-03 | 2016-03-03 | コクリエート、及び薬理活性物質の組織透過性を高めるためにそれを使用する方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US11389407B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3265060B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6770524B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20180004104A (cg-RX-API-DMAC7.html) |
| CN (1) | CN107847443A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2016226151B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2978308C (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016141203A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018337955B2 (en) * | 2017-09-20 | 2024-01-18 | Atopic Medical, Inc. | Compositions and methods for treating and ameliorating respiratory conditions and inflammation of mucosa |
| CN107621514B (zh) * | 2017-11-10 | 2020-09-29 | 成都美域高制药有限公司 | 高效液相色谱法测定磷酸特地唑胺对映异构体含量的方法 |
| KR101989789B1 (ko) * | 2017-11-30 | 2019-06-18 | (주) 에이치엔에이파마켐 | 포스파티딜세린/음이온계면활성제/염화칼슘을 이용한 코킬레이트 |
| WO2019199238A1 (en) * | 2018-04-09 | 2019-10-17 | Vet Products Research And Innovation Center Company Limited | Inorganic mineral entrapped in nanoparticle production method thereof |
| CN114269335A (zh) * | 2019-08-13 | 2022-04-01 | 马蒂纳斯生物制药纳米科技有限公司 | 治疗隐球菌感染的方法 |
| WO2024039733A1 (en) * | 2022-08-16 | 2024-02-22 | Matinas Biopharma Nanotechnologies, Inc. | Methods of controlling lipid nanocrystal particle size and lipid nanocrystals produced by such methods |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4871488A (en) | 1985-04-22 | 1989-10-03 | Albany Medical College Of Union University | Reconstituting viral glycoproteins into large phospholipid vesicles |
| US5994318A (en) | 1993-10-04 | 1999-11-30 | Albany Medical College | Cochleate delivery vehicles |
| US5643574A (en) | 1993-10-04 | 1997-07-01 | Albany Medical College | Protein- or peptide-cochleate vaccines and methods of immunizing using the same |
| US6153217A (en) | 1999-01-22 | 2000-11-28 | Biodelivery Sciences, Inc. | Nanocochleate formulations, process of preparation and method of delivery of pharmaceutical agents |
| US20030219473A1 (en) * | 2002-03-26 | 2003-11-27 | Leila Zarif | Cochleates made with purified soy phosphatidylserine |
| WO2004012709A1 (en) | 2002-08-06 | 2004-02-12 | Tuo Jin | Cochleates without metal cations as the bridging agents |
| US20050008686A1 (en) * | 2003-01-15 | 2005-01-13 | Mannino Raphael J. | Cochleate preparations of fragile nutrients |
| WO2004091578A2 (en) | 2003-04-09 | 2004-10-28 | Biodelivery Sciences International, Inc. | Novel encochleation methods, cochleates and methods of use |
| US20050013855A1 (en) | 2003-04-09 | 2005-01-20 | Biodelivery Sciences International, Inc. | Cochleate compositions directed against expression of proteins |
| JP4951338B2 (ja) * | 2003-07-16 | 2012-06-13 | プロチバ バイオセラピューティクス インコーポレイティッド | 脂質に封入された干渉ｒｎａ |
| JP2007532573A (ja) * | 2004-04-09 | 2007-11-15 | バイオデリバリー サイエンシーズ インターナショナル インコーポレイティッド | ヌクレオチド−渦巻状組成物および使用の方法 |
| CA2834788C (en) | 2011-05-05 | 2020-11-17 | Coordinated Program Development, Llc | Cochleate compositions and methods of making and using same |
| WO2013085152A1 (en) * | 2011-12-07 | 2013-06-13 | Union Korea Pharm Co., Ltd. | Combined antibiotics comprising cephalosporins and beta-lactamase inhibitors |
| EP2879502B1 (en) * | 2012-07-30 | 2018-09-05 | Matinas BioPharma Nanotechnologies, Inc. | Cochleates made with soy phosphatidylserine |
| US20180153807A1 (en) | 2015-04-22 | 2018-06-07 | Matinas Biopharma Nanotechnologies, Inc. | Compositions and methods for treating mycobacteria infections and lung disease |
| KR20180014790A (ko) | 2015-06-18 | 2018-02-09 | 마티나스 바이오파마 나노테크놀로지스, 인코포레이티드 | 염증성 질환 또는 병태를 치료하기 위한 조성물 및 방법 |
-
2016
- 2016-03-03 CN CN201680026006.3A patent/CN107847443A/zh active Pending
- 2016-03-03 EP EP16759508.1A patent/EP3265060B1/en active Active
- 2016-03-03 KR KR1020177026735A patent/KR20180004104A/ko not_active Ceased
- 2016-03-03 JP JP2017546149A patent/JP6770524B2/ja active Active
- 2016-03-03 WO PCT/US2016/020722 patent/WO2016141203A1/en not_active Ceased
- 2016-03-03 US US15/554,921 patent/US11389407B2/en active Active
- 2016-03-03 AU AU2016226151A patent/AU2016226151B2/en active Active
- 2016-03-03 CA CA2978308A patent/CA2978308C/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018508523A5 (cg-RX-API-DMAC7.html) | ||
| Peng et al. | Local release of TGF‐β inhibitor modulates tumor‐associated neutrophils and enhances pancreatic cancer response to combined irreversible electroporation and immunotherapy | |
| US11518796B2 (en) | Engineered platelets for targeted delivery of a therapeutic agent | |
| Yang et al. | Synergetic functional nanocomposites enhance immunotherapy in solid tumors by remodeling the immunoenvironment | |
| US20250195641A1 (en) | Immunotherapeutic constructs and methods of their use | |
| US10646460B2 (en) | Pharmaceutical composition for inhibiting growth of cancer stem cells, containing aldehyde inhibitor and biguanide-based compound | |
| US20170042924A1 (en) | Muscle atrophy inhibitor containing quercetin glycoside | |
| JP2016515533A5 (cg-RX-API-DMAC7.html) | ||
| CA3139714A1 (en) | Therapeutic constructs for co-delivery of mitotic kinase inhibitor and immune checkpoint inhibitor | |
| Fang et al. | Atorvastatin suppresses Toll-like receptor 4 expression and NF-κB activation in rabbit atherosclerotic plaques. | |
| ES2879881T3 (es) | Composiciones que comprenden partículas de nanosílice y su uso en métodos de activación de linfocitos T para terapia | |
| Hu et al. | Brucine inhibits bone metastasis of breast cancer cells by suppressing Jagged1/Notch1 signaling pathways | |
| Chen et al. | Leukocyte–mimicking Pluronic–lipid nanovesicle hybrids inhibit the growth and metastasis of breast cancer | |
| RU2021135194A (ru) | Способы и аппараты для подготовки клеточных популяций для клеточной терапии | |
| SI3099307T1 (en) | Use of cladribine for the treatment of neuromyelitis of the visual nerve | |
| WO2024178350A1 (en) | Methods of treating sepsis using poly(lactic acid) nanoparticles | |
| JP2018528319A (ja) | 抗転移性海洋細菌性菌体外多糖誘導体及びその使用 | |
| US20180360964A1 (en) | Pharmaceutical composition and a method for producing thereof | |
| Zavoreo et al. | Efficacy of acupuncture and vitamin C in burning mouth syndrome: A pilot study | |
| Fragassi | Rational development of intra-articular drug delivery systems for the treatment of osteoarthritis | |
| EP4588511A3 (en) | Intestinal alkaline phosphatase-based treatments of metabolic disorders | |
| KR101577271B1 (ko) | 칼슘 이온 및 친수성 비스포스포네이트를 이용한 나노복합체의 제조방법 및 상기 나노복합체를 이용한 약물전달체 | |
| Li et al. | Immunoregulatory hydrogel-fiber composite device as a local T cell activator for inhibiting glioblastoma recurrence | |
| Niknafs et al. | An Approach to New Treatments for Osteoarthritis: Advancing Phenotype-Specific Treatments and the Promise of Nanotechnology in Drug Delivery | |
| WO2025188498A1 (en) | Polymer modified nanoparticles for cytokine or other payload delivery |